NCT04518852View on ClinicalTrials.gov

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

January 31, 2023

Conditions
Hepatocellular CarcinomaLiver NeoplasmsDigestive System NeoplasmsSorafenibMolecular Mechanisms of Pharmacological ActionLiver DiseasesAntineoplastic AgentsProtein Kinase Inhibitors
Interventions
COMBINATION_PRODUCT

TACE combined with sorafenib and PD-1 mAb

the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)

Trial Locations (1)

610041

Sichuan Cancer Hospital and Research Institute, Chengdu

All Listed Sponsors
lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | Biotech Hunter | Biotech Hunter